Costunolide, a natural sesquiterpene lactone, has multiple pharmacological activities such as neuroprotection or induction of apoptosis and eryptosis. However, the effects of costunolide on pro-survival factors and enzymes in human erythrocytes, e.g. glutathione and glucose-6-phosphate dehydrogenase (G6PDH) respectively, have not been studied yet. Our aim was to determine the mechanisms underlying costunolide-induced eryptosis and to reverse this process. Phosphatidylserine exposure was estimated from annexin-V-binding, cell volume from forward scatter in flow cytometry, and intracellular glutathione [GSH]i from high performance liquid chromatography. The oxidized status of intracellular glutathione and enzyme activities were measured by spectrophotometry. Treatment of erythrocytes with costunolide dose-dependently enhanced the percentage of annexin-V-binding cells, decreased the cell volume, depleted [GSH]i and completely inhibited G6PDH activity. The effects of costunolide on annexin-V-binding and cell volume were significantly reversed by pre-treatment of erythrocytes with the specific PKC-α inhibitor chelerythrine. The latter, however, had no effect on costunolide-induced GSH depletion. Costunolide induces eryptosis, depletes [GSH]i and inactivates G6PDH activity. Furthermore, our study reveals an inhibitory effect of chelerythrine on costunolide-induced eryptosis, indicating a relationship between costunolide and PKC-α. In addition, chelerythrine acts independently of the GSH depletion. Understanding the mechanisms of G6PDH inhibition accompanied by GSH depletion should be useful for development of anti-malarial therapeutic strategies or for synthetic lethality-based approaches to escalate oxidative stress in cancer cells for their sensitization to chemotherapy and radiotherapy.

• MeSH
• apoptóza účinky léků   MeSH
• benzofenantridiny farmakologie   MeSH
• eryptóza účinky léků   genetika   MeSH
• erytrocyty účinky léků   patologie   MeSH
• glukosa-6-fosfátdehydrogenasa antagonisté a inhibitory   genetika   MeSH
• glutathion genetika   MeSH
• inhibitory enzymů farmakologie   MeSH
• lidé MeSH
• oxidační stres účinky léků   MeSH
• proteinkinasa C-alfa antagonisté a inhibitory   genetika   MeSH
• reaktivní formy kyslíku MeSH
• seskviterpeny farmakologie   MeSH
• vápník metabolismus   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH

BACKGROUND: Randomized controlled studies of combination therapies in rosacea are limited. OBJECTIVE: Evaluate the efficacy and safety of combining ivermectin 1% cream (IVM) and doxycycline 40-mg modified-release capsules (ie, 30-mg immediate-release and 10-mg delayed-release beads) (DMR) versus IVM and placebo for treatment of severe rosacea. METHODS: This 12-week, multicenter, randomized, investigator-blinded, parallel-group comparative study randomized adult subjects with severe rosacea (Investigator's Global Assessment [IGA] score, 4) to receive either IVM and DMR (combination arm) or IVM and placebo (monotherapy). RESULTS: A total of 273 subjects participated. IVM and DMR displayed superior efficacy in reduction of inflammatory lesions (-80.3% vs -73.6% for monotherapy [P = .032]) and IGA score (P = .032). Combination therapy had a faster onset of action as of week 4; it significantly increased the number of subjects achieving an IGA score of 0 (11.9% vs 5.1% [P = .043]) and 100% lesion reduction (17.8% vs 7.2% [P = .006]) at week 12. Both treatments reduced the Clinician's Erythema Assessment score, stinging/burning, flushing episodes, Dermatology Life Quality Index score, and ocular signs/symptoms and were well tolerated. LIMITATIONS: The duration of the study prevented evaluation of potential recurrences or further improvements. CONCLUSION: Combining IVM and DMR can produce faster responses, improve response rates, and increase patient satisfaction in cases of severe rosacea.

• MeSH
• aplikace orální MeSH
• časové faktory MeSH
• dospělí MeSH
• doxycyklin aplikace a dávkování   MeSH
• ivermektin aplikace a dávkování   MeSH
• kombinovaná farmakoterapie metody   MeSH
• kvalita života MeSH
• léky s prodlouženým účinkem aplikace a dávkování   MeSH
• lidé MeSH
• placeba aplikace a dávkování   MeSH
• pleťový krém aplikace a dávkování   MeSH
• rosacea komplikace   diagnóza   farmakoterapie   MeSH
• spokojenost pacientů MeSH
• stupeň závažnosti nemoci MeSH
• tobolky MeSH
• výsledek terapie MeSH
• Check Tag
• dospělí MeSH
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• klinické zkoušky, fáze III MeSH
• klinické zkoušky, fáze IV MeSH
• multicentrická studie MeSH
• randomizované kontrolované studie MeSH
• srovnávací studie MeSH

Publikace, která slouží zejména dermatologům k opakování, je určena také ostatním lékařům v praxi – praktikům, internistům, pediatrům i lékařům dalších odborností, dále studentům medicíny, ale i zdravotnických škol. Krátká a precizní definice nemoci je v knize vždy vlevo – vpravo najdete schémata, obrázky nebo fotografie. Na 190 barevných tabulí. Autoři jsou významní zahraniční odborníci. Přeloženo z originálu COLOR ATLAS OF DERMATOLOGY, který vydalo nakladatelství Thieme. Překlad recenzovala prof. MUDr. Petra Cetkovská, Ph.D. Nakladatelská anotace

• MeSH
• dermatologie MeSH
• kožní nemoci MeSH
• sexuálně přenosné nemoci MeSH
• Publikační typ
• atlasy MeSH

• Konspekt
• Patologie. Klinická medicína
• NLK Obory
• dermatovenerologie